NCT02684266View on ClinicalTrials.gov

A Study of SHR6390 in Advanced Solid Tumor Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 3, 2016

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Neoplasm
Interventions
DRUG

SHR6390

SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD

Trial Locations (1)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT02684266 - A Study of SHR6390 in Advanced Solid Tumor Patients | Biotech Hunter | Biotech Hunter